{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.9","upperLimit":"6.1","value":"2.6"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"189"}],"units":"Participants"}],"description":"Partial Remission is defined as bone marrow blasts 6% to 25% with at least a 50% reduction from baseline.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received blinatumomab by continuous intravenous (CIV) infusion over 4 weeks followed by a treatment-free interval of 2 weeks for up to 5 consecutive cycles. The initial dose was 9 μg/day for the first seven days of treatment, escalated to 28 μg/day starting from Week 2 of treatment.","id":"OG000","title":"Blinatumomab"}],"paramType":"NUMBER","populationDescription":"Primary analysis set","reportingStatus":"POSTED","timeFrame":"Within the first 2 cycles of treatment, 12 weeks","title":"Percentage of Participants With a Best Response of Partial Remission Within 2 Cycles of Treatment","type":"SECONDARY","unitOfMeasure":"percentage of participants"}